Skip to main content
Article thumbnail
Location of Repository

Pharmacological manipulation of cyclic GMP levels in brain restores learning ability in animal models of hepatic encephalopathy: therapeutic implications

By Regina Rodrigo, Pilar Monfort, Omar Cauli, Slaven Erceg and Vicente Felipo


Hepatic encephalopathy (HE) is a complex neuropsychiatric syndrome present in patients with liver disease that includes impaired intellectual function. To develop therapeutic treatments to restore cognitive function, it is important to understand the molecular mechanisms that impair cognitive function in HE. This review summarizes data showing that: (a) cognitive function and learning are impaired in patients with liver disease and in animal models of chronic liver failure or hyperammonemia; (b) the glutamate–NO–cGMP pathway modulates some forms of learning; and (c) the function of this pathway is impaired in brain in vivo in rats with chronic hyperammonemia or liver failure and from patients who died from HE. Learning ability of hyperammonemic rats was restored by increasing cGMP by: (1) continuous intracerebral administration of zaprinast, an inhibitor of the cGMP-degrading phosphodiesterase; (2) chronic oral administration of sildenafil, an inhibitor of the phosphodiesterase that crosses the blood–brain barrier; and (3) continuous intracerebral administration of cGMP. The data summarized indicate that impairment of learning ability in rats with chronic liver failure or hyperammonemia is due to impairment of the glutamate–NO–cGMP pathway. Moreover, increasing extracellular cGMP by pharmacological means may be a new therapeutic approach to improve cognitive function in patients with HE

Topics: Reviews
Publisher: Dove Medical Press
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2000). Chronic moderate hyperammonemia impairs active and passive avoidance behavior and conditional discrimination learning in rats. Exp Neurol,
  2. (1996). Diagnostic tools for the detection of subclinical hepatic encephalopathy:comparison of standard and computerized psychometric tests with spectral-EEG. Metab Brain Dis,
  3. (1999). Clinical features and survival of cirrhotic patients with subclinical cognitive alterations detected by the number connection test and computerized psychometric tests.
  4. (1999). Spectral versus visual EEG analysis in mild hepatic encephalopathy Clin Neurophysiol,
  5. (2001). Prevalence and prognostic value of quantifi ed electroencephalogram (EEG) alterations in cirrhotic patients.
  6. (2004). Characteristics of minimal hepatic encephalopathy. Metab Brain Dis,
  7. (1998). Diurnal and gender effects by chronic portacaval shunting in rats on spontaneous locomotor and rearing activities in an open-fi eld.
  8. (1999). Altered adaptive behaviour expressed in an open-fi eld paradigm in experimental hepatic encephalopathy. Behav Brain Res,
  9. (1989). A simple animal model of hyperammonemia.
  10. (1986). Portacaval shunt in the rat: selective alterations in behavior and brain serotonin. Pharmacol Biochem Behav,
  11. (1989). Brain 5-HT1 and 5-HT2 binding sites following portacaval shunt in the rat. Res Exp Med,
  12. (1997). Further evidence for the involvement of a hippocampal cGMP/cGMP-dependent protein kinase cascade in memory consolidation.
  13. (2004). Lack of detrimental effects of nitric oxide inhibition in bile duct-ligated rats with hepatic encephalopathy.
  14. (1997). Memory-related changes of nitric oxide synthase activity and nitrite level in rat brain.
  15. (2002). Region selective alterations of soluble guanylate cyclase content and modulation in brain of cirrhotic patients.
  16. (1997). Stenosis of a portacaval anastomosis affects circadian locomotor activity in the rat:a multivariable analysis.
  17. (1998). High prevalence of sleep disturbance in cirrhosis.
  18. (1995). Modulation of learning processes by ionotropic glutamate receptor ligands. Behav Pharmacol,
  19. (1996). Effects of MK-801 on acquisition, retention and crossmodal transfer of active avoidance behaviour in rats.
  20. (1975). Cognitive defi cit associated with chronic hepatic encephalopathy and their response to levodopa.
  21. (2005). Oral administration of sildenafi l restores learning ability in rats with hyperammonemia and with portacaval shunts.
  22. (2005). Restoration of learning ability in hyperammonemic rats by increasing extracellular cGMP in brain.
  23. (1984). Changes in glutamate receptors on synaptic membranes associated with hepatic encephalopathy or hyperammonemia in the rabbit. Hepatology, 4:25–9.Neuropsychiatric Disease and Treatment 2006:2(1) 62 Rodrigo et al Ferenci
  24. (2005). Evaluation of two experimental models of hepatic encephalopathy in rats.
  25. (2000). Choline release and inhibition of phosphatidylcholine synthesis precede excitotoxic neuronal death but not neurotoxicity induced by serum deprivation.
  26. (1980). Psychomotor performance defects in cirrhotic patients without overt encephalopathy.
  27. (1998). Subclinical hepatic encephalopathy impairs daily functioning.
  28. (2000). The prognostic signifi cance of subclinical hepatic encephalopathy.
  29. (2002). Neuronal nitric oxide has a role as a perfusion regulator and a synaptic modulator in cerebellum but not in neocortex during somatosensory stimulation—an animal PET study. Neurosci Res,
  30. (1998). Chronic hyperammonemia impairs glutamate-nitric oxide-cyclic GMP pathway in cerebellar neurons in culture and in the rat in vivo.
  31. (2000). Formation of temporal memory requires NMDA receptors within CA1 pyramidal neurons.
  32. (1982). Melatonin serum levels and metabolic clearance rate in patients with liver cirrhosis.
  33. (1998). Intraventricular injection of N-nitro-L-arginine in rats impairs learning in a 14-unit T- maze.
  34. (1998). Learning in a 14-unit T-maze is impaired in rats following the systemic treatmentwith N-nitro-L-arginina.
  35. (1991). Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy.
  36. (2002). Cytochrome oxidase activity of the suprachiasmatic nucleus and pineal gland in rats with portacaval shunt. Exp Neurol,
  37. (2000). Effects of the histamine H(1) receptor blocker, pyrilamine, on spontaneous locomotor activity of rats with long-term portacaval anastomosis.
  38. (2002). Effect of repeated L-histidine administration on plasma prolactin and growth hormone levels in rats. Infl amm Res,
  39. (1996). Neuropsychological characterization and detection of subclinical hepatic encephalopathy.
  40. (1996). Impaired hippocampal representation of space in CA1-specifi c NMDAR1 knockout mice.
  41. (1986). Behavioral effects of experimental portacaval anastomosis measured in Dashiell and radial tunnel maze confi gurations. Physiol Behav,
  42. (1994). PRE-084, a sigma selective PCP derivative, attenuates MK-801-induced impairment of learning in mice.
  43. (1998). Combined stimulation of the glycine and polyamine sites of the NMDA receptor attenuates NMDA blockade-induced learning defi cits of rats in a 14-unit-T-maze. Psychopharmacology,
  44. (2001). Altered content and modulation of soluble guanylate cyclase in the cerebellum of rats with portacaval anastomosis.
  45. (1999). Role of cyclic GMP in glutamate neurotoxicity in primary cultures of cerebellar neurons.
  46. (1983). The release and neosynthesis of glutamic acid are increased in experimental models of hepatic encephalopathy.
  47. (1986). Allocentric spatial learning by hippocampectomised rats:a further test of the “spatial mapping” and “working memory” theories of hippocampal function.
  48. (1997). Inhibitory learning and memory in new-born rats.
  49. (1997). The effect of dizocilpine (MK-801) on conditional discrimination learning in the rat. Behav Pharmacol,
  50. (1997). Posttraining injections of MK-801 procedure a time- dependent impairment of memory in two water maze tasks. Neurobiol Learn Mem,
  51. (1999). The type and the localization of cAMP-dependent protein kinase regulate transmission of cAMP signals to the nucleus in cortical and cerebellar granule cells.
  52. (1990). Excitatory amino acid antagonists and memory:effect of drugs acting at N-methyl-D-aspartate receptors in learning and memory tasks.
  53. (1957). The electroencephalograph in liver disease.
  54. (1998). Phenserine, a novel acetylcholinesterase inhibitor, attenuates impaired learning of rats in a 14-unit T-maze induced by blockade of the N-methyl-D-aspartate receptor.
  55. (1997). Possible role of nitric oxide –cyclic GMP pathway in object recognition memory:Effects of 7-nitroindazole and zaprinast.
  56. (2002). cGMP, but not cAMP, in rat hippocampus is involved in early stages of object memory consolidation.
  57. (2000). Genetic analysis of learning behaviour-induced structural plasticity.
  58. (1998). Efectos de la administración aguda de MK-801, antagonista no competitivo de los receptores NMDA, sobre la evitación activa en ratones.
  59. (1977). Chronic hepatic encephalopathy A psychometrical study.
  60. (1996). Effects of combined block of alpha 1-adrenoceptors and NMDA receptors on spatial and passive avoidance behaviour in rats.
  61. (1978). Subclinical hepatic encephalopathy:detection, prevalence, and relationship to nitrogen metabolism.
  62. (2005). Bile duct ligation plus hyperammonemia in rats reproduces the alterations in the modulation of soluble guanylate cyclase by nitric oxide in brain of cirrhotic patients.
  63. (2001). Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy.
  64. (1995). Reduced hippocampal LTP and spatial learning in mice lacking NMDA receptor epsilon 1 subunit. Nature, 373:151–5.Neuropsychiatric Disease and Treatment 2006:2(1) 63 cGMP and cognitive function in hepatic encephalopathy
  65. (2001). Quality of life in cirrhotics with minimal hepatic encephalopathy. Metab Brain Dis,
  66. (1981). Latent portasystemic encephalopathy. I. Nature of cerebral functional defects and their effect on fi tness to drive. Dig Dis Sci,
  67. (1997). Coffi n VL.
  68. (2000). A novel nitrate ester reverses the cognitive impairment caused by scopolamine in the Morris water maze.
  69. (1994). Fitness to drive in patients with cirrhosis and portal-systemic shunting:a pilot study evaluating driving performance.
  70. (1995). Disruption of the diurnal rhythm of plasma melatonin in cirrhosis.
  71. (1996). A low-protein diet ameliorates disrupted diurnal locomotor activity in rats after portacaval anastomosis.
  72. (1999). Genetic enhancement of learning and memory in mice.
  73. (1984). Nonalcoholic cirrhosis associated with neuropsychological dysfunction in the absence of overt evidence of hepatic encephalopathy.
  74. et al.1987. Memory impairments concomitant with nonalcoholic cirrhosis.
  75. (2005). Inhibition of cGMP-specifi c phosphodiesterase type 5 reduces sodium excretion and arterial blood pressure in patients with NaCl retention and ascites.
  76. (1044). The essential role of hippocampal CA1 NMDA receptor-dependent synaptic plasticity in spatial memory.
  77. (2002). Sildenafi l (viagra) is a risk factor for acute variceal bleeding.
  78. (1992). Quantitative EEG analysis and evoked potentials to measure (latent) hepatic encephalopathy.
  79. (2003). Ammonia levels and the severity of hepatic encephalopathy.
  80. (2001). Attention defi cits in minimal hepatic encephalopathy. Metab Brain Dis,
  81. (2003). Memory function in early hepatic encephalopathy.
  82. (1997). NMDA receptor antagonist MK-801 selectively impairs learning of the contiguity of the conditioned stimulus and unconditioned stimulus in goldfi sh.
  83. (1996). Role of nitric oxide and cyclic GMP in the dizocilpine-induced impairment of spontaneous alternation behavior in mice.
  84. (1991). Portacaval anastomosis disrupts circadian locomotor activity and pineal melatonin rhythms in rats.
  85. (1998). Nitric oxide synthase inhibitors impair reference memory formation in a radial arm maze task in rats.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.